Research programme: uPARAP-targeting antibody drug conjugates - University of Copenhagen/ADCendo

Drug Profile

Research programme: uPARAP-targeting antibody drug conjugates - University of Copenhagen/ADCendo

Alternative Names: Monomethyl auristatin E-conjugated antibody - University of Copenhagen/ADCendo

Latest Information Update: 10 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Rigshospitalet; University of Copenhagen
  • Developer ADCendo; Rigshospitalet; University of Copenhagen
  • Class Antineoplastics; Auristatins; Immunoconjugates
  • Mechanism of Action Mitosis inhibitors; Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 24 Sep 2016 Preclinical data in Cancer released by University of Copenhagen
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top